Q-omics provides the consensus-scored TPI1P2 profile across patient tissues and cancer cell-line models. TPI1P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TPI1P2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TPI1P2 RNA expression shows 18,992 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where TPI1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPI1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPI1P2 survival associations across molecular data types. TPI1P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPI1P2 RNA expression–survival associations across cancer types. High TPI1P2 expression shows unfavorable associations in MESO and CHOL, but favorable associations in UCS, LUSC, OV and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .017). Together, the overview and detailed table identify UCS as the clearest survival context for TPI1P2 RNA expression.
This table summarizes TPI1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TPI1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPI1P2 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in BLCA, HNSC and LUAD. The KIRC box plot shows higher TPI1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.819, t-test p < 0.001).
This table shows molecular features associated with TPI1P2 in patient tissues and cancer cell lines. In patient samples, TPI1P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPI1P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
